Exelixis ((EXEL)), Novartis AG ((NVS)), Bristol-Myers Squibb Company ((BMY)), Clovis Oncology Inc ((CLVSQ)), DEL_Novartis (0QM7) ((DEL_0QM7)), DEL_Novartis Inc ((DEL_0QLR)), Novartis ((CH:NOVN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Pan-Tumor Rollover Study, officially titled ‘Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,’ aims to assess the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This study is significant as it explores the extended use of these treatments, potentially offering new insights into cancer management.
The study tests several interventions, primarily focusing on the drug nivolumab, either alone or in combination with other drugs like ipilimumab, cabozantinib, and relatlimab. These interventions are designed to evaluate their safety and efficacy in treating different cancer types.
Designed as an interventional study, it follows a non-randomized, parallel assignment model without masking, focusing on treatment as its primary purpose. This straightforward design allows for a clear assessment of the treatment’s long-term safety.
The study began on August 9, 2019, with its primary completion and estimated completion dates yet to be updated. The latest update was submitted on July 31, 2025, highlighting the ongoing nature of the research.
This study update could influence stock performance and investor sentiment for involved companies like Bristol-Myers Squibb, Exelixis, and Novartis. Positive results may boost investor confidence and market position, while the competitive landscape remains dynamic with ongoing advancements in cancer therapies.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.